1357247-47-2

Usage

Uses

Used in Organic Synthesis:
(trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate is used as an intermediate in the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of molecules with different properties and applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate is used as a key component in the development of new pharmaceuticals. Its structural diversity makes it a valuable asset for designing molecules with specific biological activities.
Used in the Treatment of Medical Conditions:
Although further research is required, (trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate may have potential applications in the treatment of various medical conditions. Its incorporation into pharmaceuticals could lead to the development of novel therapies for a range of diseases.
Used in the Synthesis of Biologically Active Molecules:
Due to its structural features, (trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate is also utilized in the synthesis of biologically active molecules. These molecules can be used in research to understand various biological processes or can be developed into potential therapeutic agents.

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 656827-74-6 ethyl (E)-3-(6-bromo-3-pyridinyl)-2-propenoate 
• 149806-06-4 6-bromonicotinaldehyde 

Relevant academic research and scientific papers

CYCLOPROPYLAMINE INHIBITORS OF OXIDASES

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.

CYCLOPROPYLAMINE INHIBITORS OF OXIDASES

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.

ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).